The FDA has approved Acuvail (ketorolac tromethamine 0.45%, Allergan), a preservative-free formulation of the nonsteroidal anti-inflammatory drug ketorolac. Acuvail is indicated for the treatment of pain and inflammation following cataract surgery. A clinical study found that at one day after cataract surgery, 72% of patients treated with ketorolac demonstrated pain scores of zero, compared with 40% of patients in the vehicle group. Acuvail is expected to be available in September, Allergan says.